Immune-Oncology Innovations: The Future of Cancer Treatment With ICIs, CAR-T, and CAR-NK Cell Therapies
November 30, 2024
November 30, 2024
SAN ANTONIO, Texas, Nov. 30 (TNSres) -- Frost and Sullivan, a provider of market research and analysis, growth strategy consulting and corporate training services, issued the following news release on Nov. 29, 2024:
The landscape of immune-oncology (I-O) is rapidly evolving, driven by groundbreaking innovations in cell therapies and immune checkpoint inhibitors (ICIs). As the leading class of I-O agents, ICIs continue to be a foundational treatment for various cancers, while emergin . . .
The landscape of immune-oncology (I-O) is rapidly evolving, driven by groundbreaking innovations in cell therapies and immune checkpoint inhibitors (ICIs). As the leading class of I-O agents, ICIs continue to be a foundational treatment for various cancers, while emergin . . .